Also found in: Medical, Wikipedia.


An oral antipsychotic drug, C28H27FN4O2, that is a dopamine and serotonin antagonist and is used to treat schizophrenia and bipolar disorder.

[Perhaps (fluo)r(obenz)is(oxazole), one of its constituents (fluoro- + benz- + is(o)- + ox- + azole) + (pi)perid(ine) + -one.]


n risperidona
References in periodicals archive ?
Adjunctive treatment with risperidone was superior to antidepressant monotherapy for participants without a significant response in OCD symptom severity of at least 25% with validated measures (OR 0.
Clozapine, olanzapine, and oral and long-acting injectable formulations of risperidone proved superior on more schizophrenia outcomes that did other second-generation antipsychotics, according to a review of the effectiveness of treatments for adults with the illness.
10] More interestingly, some studies showed the SNP (single nucleotide polymorphism) subtypes, rs4795893, rs1024611, rs4586 and rs2857657, of CCL2, the coding gene of MCP-1, were associated with treatment resistance of risperidone in the Han Chinese population.
In the literature, there is only one case on hyperacusis that worsened with risperidone in a 5-year-old girl with autism.
Braeburn Pharmaceuticals is making waves in the study of schizophrenia as it announced on Monday that it had completed its six-month study that examined the transition from oral risperidone to BB0817 (risperidone) implant and had achieved its primary endpoint.
Total quantity or scope: Risperidone solution for injection 1x25 mg, quantity 144;
The findings come from a responder analysis of an open-label study of risperidone (Risperdal) use in Alzheimer's patients who express neuropsychiatric symptoms.
Risperidone and aripiprazole, followed by N-acetylcysteine, appear most effective in treating irritability and aggression in youth with autism spectrum disorders (ASD).
In the present study, supplementation with NAC as an adjunct to risperidone improved irritability and hyperactivity/noncompliance in children with autistic disorders.
1 May 2015 - US-based drugmaker Braeburn Pharmaceuticals has acquired an implantable, six-month formulation of the atypical (or second-generation) antipsychotic risperidone for treatment of schizophrenia from Endo Pharmaceuticals, the company said on Friday.
For example, current approved drugs by the Food and Drug Administration (FDA) such as risperidone and aripiprazole have not been proven to pose significant effect on the core features of this disorder (2-4).
Patients and Methods: A total of 110 patients were assigned to treatment with haloperidol (n=35), risperidone (n=36) and olanzapine (n=39).